Syndax Pharmaceuticals
SNDX
80 hedge funds and large institutions have $150M invested in Syndax Pharmaceuticals in 2017 Q4 according to their latest regulatory filings, with 21 funds opening new positions, 27 increasing their positions, 19 reducing their positions, and 9 closing their positions.
133% more first-time investments, than exits
New positions opened: 21 | Existing positions closed: 9
100% more funds holding in top 10
Funds holding in top 10: 1 → 2 (+1)
42% more repeat investments, than reductions
Existing positions increased: 27 | Existing positions reduced: 19
18% more funds holding
Funds holding: 68 → 80 (+12)
2.74% more ownership
Funds ownership: 67.67% → 70.41% (+2.7%)
15% less capital invested
Capital invested by funds: $176M → $150M (-$25.6M)
100% less call options, than puts
Call options by funds: $0 | Put options by funds: $9K
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BI
BVF Inc
San Francisco,
California
|
+$32M |
| 2 |
Wellington Management Group
Boston,
Massachusetts
|
+$3.08M |
| 3 |
Dimensional Fund Advisors
Austin,
Texas
|
+$1.67M |
| 4 |
Vanguard Group
Malvern,
Pennsylvania
|
+$862K |
| 5 |
OAM
Oxford Asset Management
Oxford,
United Kingdom
|
+$858K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
-$7.94M |
| 2 |
ACH
ArrowMark Colorado Holdings
Denver,
Colorado
|
-$5.82M |
| 3 |
Jennison Associates
New York
|
-$4.16M |
| 4 |
Fidelity Investments
Boston,
Massachusetts
|
-$3.91M |
| 5 |
EAM
Eventide Asset Management
Boston,
Massachusetts
|
-$2.63M |
SNDX Hedge Fund Activity: Q4 2017 in Review
80 of the 4,409 institutional investors tracked by Wall St. Rank reported a position in Syndax Pharmaceuticals (SNDX) for Q4 2017, worth a combined $150M — down 15% from $176M a quarter earlier.
Buyers outnumbered sellers: 21 funds opened new SNDX positions and 9 closed out — a net gain of 12 holders — while 27 added to existing stakes and 19 trimmed.
The largest buyer was BVF Inc, opening a new position worth an estimated $32M. The largest seller was BlackRock, cutting an estimated $7.94M.
- 80 institutional investors held Syndax Pharmaceuticals (SNDX) as of Q4 2017, up from 68 in Q3 2017.
- Funds reported $150M of Syndax Pharmaceuticals stock for Q4 2017, down 15% quarter-over-quarter.
- 21 funds opened new Syndax Pharmaceuticals positions in Q4 2017 and 9 closed out, a net change of +12 holders.
- The largest Syndax Pharmaceuticals buyer in Q4 2017 was BVF Inc, an estimated $32M added.
- The largest Syndax Pharmaceuticals seller in Q4 2017 was BlackRock, an estimated $7.94M sold.
Based on aggregated 13F filings for Q4 2017.